Analysts Offer Predictions for Immunocore Q2 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Leerink Partnrs issued their Q2 2025 earnings estimates for Immunocore in a research note issued on Wednesday, February 26th. Leerink Partnrs analyst J. Chang expects that the company will earn ($0.39) per share for the quarter. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore’s Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.41) EPS and FY2026 earnings at ($2.38) EPS.

Several other research analysts also recently commented on IMCR. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, January 27th. Morgan Stanley restated an “equal weight” rating and set a $35.00 price objective (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research note on Friday, January 10th. Finally, Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Price Performance

Shares of NASDAQ:IMCR opened at $30.77 on Thursday. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $1.54 billion, a PE ratio of -32.39 and a beta of 0.77. The firm has a 50 day moving average of $30.03 and a 200-day moving average of $31.96. Immunocore has a 12 month low of $27.69 and a 12 month high of $72.56.

Hedge Funds Weigh In On Immunocore

Hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its position in Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after acquiring an additional 109,206 shares during the last quarter. Assetmark Inc. boosted its holdings in Immunocore by 6.5% in the third quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock valued at $951,000 after acquiring an additional 1,878 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in Immunocore during the 3rd quarter valued at approximately $866,000. Finally, GSA Capital Partners LLP bought a new position in Immunocore during the 3rd quarter worth approximately $406,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.